{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:21:24Z","timestamp":1773663684924,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2300400"],"award-info":[{"award-number":["2021YFC2300400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["HS2021SHZX001"],"award-info":[{"award-number":["HS2021SHZX001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12841-6","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:46:19Z","timestamp":1770702379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of amphotericin B colloidal dispersion in the treatment of mucormycosis: a real-world observation"],"prefix":"10.1186","volume":"26","author":[{"given":"Ying-Kui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Tian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Sheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"12841_CR1","unstructured":"Organization WH. WHO fungal priority pathogens list to guide research, development and public health action 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240060241. Accessed 21 Sep 2024."},{"issue":"7","key":"12841_CR2","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428\u201338.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"12841_CR3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3201\/eid2609.200016","volume":"26","author":"LH Zhou","year":"2020","unstructured":"Zhou LH, Jiang YK, Li RY, Huang LP, Yip CW, Denning DW, et al. Risk-based estimate of human fungal disease burden, China. Emerg Infect Dis. 2020;26(9):2137\u201347.","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"12841_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3201\/eid2901.220926","volume":"29","author":"V Muthu","year":"2023","unstructured":"Muthu V, Agarwal R, Rudramurthy SM, Thangaraju D, Shevkani MR, et al. Multicenter case-control study of COVID-19-associated mucormycosis outbreak, India. Emerg Infect Dis. 2023;29(1):8\u201319.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"12841_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","volume":"47","author":"G Chamilos","year":"2008","unstructured":"Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"12841_CR6","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in Cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"12841_CR7","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S1473-3099(22)00124-4","volume":"22","author":"V Muthu","year":"2022","unstructured":"Muthu V, Agarwal R, Patel A, Kathirvel S, Abraham OC, Aggarwal AN, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the fungal infection study forum and academy of pulmonary Sciences, India. Lancet Infect Dis. 2022;22(9):e240\u201353.","journal-title":"Lancet Infect Dis"},{"key":"12841_CR8","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.2147\/IDR.S481856","volume":"17","author":"M Liu","year":"2024","unstructured":"Liu M, Yang H, Liu Q, He K, Yuan J, Chen Y. Amphotericin B colloidal dispersion is efficacious and safe for the management of talaromycosis in HIV-infected patients: results of a retrospective cohort study in China. Infect Drug Resist. 2024;17:5581\u201393.","journal-title":"Infect Drug Resist"},{"key":"12841_CR9","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/IDR.S494985","volume":"18","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang Q, Ma W, Chu ZB, Xu L, Xing H, et al. Efficacy and safety of amphotericin B colloidal dispersion for patients with invasive fungal disease and febrile neutropenia: a registry-based, multicenter, retrospective, real-world study. Infect Drug Resist. 2025;18:2475\u201387.","journal-title":"Infect Drug Resist"},{"key":"12841_CR10","doi-asserted-by":"publisher","first-page":"1147624","DOI":"10.3389\/fcimb.2023.1147624","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu J, Ma X. Amphotericin B colloidal dispersion: an effective drug for the treatment of mucormycosis in China. Front Cell Infect Microbiol. 2023;13:1147624.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"12841_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1086\/341401","volume":"35","author":"R Bowden","year":"2002","unstructured":"Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(4):359\u201366.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12841_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1086\/514672","volume":"27","author":"MH White","year":"1998","unstructured":"White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27(2):296\u2013302.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12841_CR13","first-page":"230","volume":"63","author":"Medical Mycology Society of Chinese Medicine and Education Association","year":"2024","unstructured":"Medical Mycology Society of Chinese Medicine and Education Association. Multidisciplinary expert consensus on the clinical rational application of different formulations of amphotericin B (2024 edition). Zhonghua Nei Ke Za Zhi. 2024;63(3):230\u201357.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"12841_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"12841_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","volume":"47","author":"BH Segal","year":"2008","unstructured":"Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis. 2008;47(5):674\u201383.","journal-title":"Clin Infect Dis"},{"key":"12841_CR16","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE, version 5.0). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 21 Sep 2024."},{"key":"12841_CR17","unstructured":"World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf. Accessed 21 Sep 2024."},{"issue":"Suppl 1","key":"12841_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"12841_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344.","journal-title":"Haematologica"},{"issue":"6","key":"12841_CR20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jac\/dkl141","volume":"57","author":"H Vogelsinger","year":"2006","unstructured":"Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"12841_CR21","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.clinthera.2021.09.012","volume":"43","author":"ZW Huang","year":"2021","unstructured":"Huang ZW, Yu JC, Wang JJ, Chen YC, Wu JF, Chen YJ, et al. Pharmacokinetics and safety of single-dose amphotericin B colloidal dispersion in healthy Chinese subjects and population pharmacokinetic\/pharmacodynamic analysis to inform clinical efficacy in invasive infections caused by Candida albicans. Clin Ther. 2021;43(11):1921\u2013e337.","journal-title":"Clin Ther"},{"issue":"4","key":"12841_CR22","first-page":"635","volume":"24","author":"MH White","year":"1997","unstructured":"White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997;24(4):635\u201342.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"12841_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jiac.2020.10.005","volume":"27","author":"M Yoshida","year":"2021","unstructured":"Yoshida M, Tamura K, Masaoka T, Nakajo E. A real-world prospective observational study on the efficacy and safety of liposomal amphotericin B in 426 patients with persistent neutropenia and fever. J Infect Chemother. 2021;27(2):277\u201383.","journal-title":"J Infect Chemother"},{"issue":"1","key":"12841_CR24","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.mycmed.2022.101332","volume":"33","author":"DS Meena","year":"2023","unstructured":"Meena DS, Kumar D, Bohra GK. Combination therapy in mucormycosis: current evidence from the world literature, a mini review. J Mycol Med. 2023;33(1):101332.","journal-title":"J Mycol Med"},{"issue":"10","key":"12841_CR25","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Cornely OA, Busca A, Caira M, Cesaro S, Gasbarrino C, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127\u201330.","journal-title":"Haematologica"},{"issue":"9","key":"12841_CR26","doi-asserted-by":"publisher","first-page":"e811811","DOI":"10.1016\/j.cmi.2016.03.029","volume":"22","author":"A Kyvernitakis","year":"2016","unstructured":"Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22(9):e811811\u201318.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"12841_CR27","doi-asserted-by":"publisher","first-page":"ofaa646","DOI":"10.1093\/ofid\/ofaa646","volume":"8","author":"MA Miller","year":"2021","unstructured":"Miller MA, Molina KC, Gutman JA, Scherger S, Lum JM, Mossad SB, et al. Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents. Open Forum Infect Dis. 2021;8(2):ofaa646.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"12841_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11046-024-00875-w","volume":"189","author":"J Wang","year":"2024","unstructured":"Wang J, Liu L, Li J, Feng X, Yi H, Jiang E, et al. Clinical characteristics, prognosis factors and metagenomic next-generation sequencing diagnosis of mucormycosis in patients with hematologic diseases. Mycopathologia. 2024;189(4):71.","journal-title":"Mycopathologia"},{"issue":"3","key":"12841_CR29","doi-asserted-by":"publisher","first-page":"107440","DOI":"10.1016\/j.ijantimicag.2024.107440","volume":"65","author":"M Yan","year":"2025","unstructured":"Yan M, Shang L, Wang Y, Wang C, Cao B. Metagenomic next-generation sequencing on treatment strategies and prognosis of patients with lower respiratory tract infections: A systematic review and meta-analysis. Int J Antimicrob Agents. 2025;65(3):107440.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"12841_CR30","first-page":"28","volume":"48","author":"Chinese Society of Laboratory Medicine","year":"2025","unstructured":"Chinese Society of Laboratory Medicine. Chinese expert consensus on quality control of bioinformatics analysis and standardized report for pathogen metagenomic next-generation sequencing. Chin J Lab Med. 2025;48(1):28\u201337.","journal-title":"Chin J Lab Med"},{"issue":"9","key":"12841_CR31","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.cmi.2024.03.003","volume":"30","author":"SY Park","year":"2024","unstructured":"Park SY, Ardura MI, Zhang SX. Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematological malignancies. Clin Microbiol Infect. 2024;30(9):1139\u201346.","journal-title":"Clin Microbiol Infect"},{"key":"12841_CR32","doi-asserted-by":"publisher","first-page":"103115","DOI":"10.1016\/j.eclinm.2025.103115","volume":"81","author":"L Brown","year":"2025","unstructured":"Brown L, Tschiderer L, Alanio A, et al. The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis. EClinicalMedicine. 2025;81:103115.","journal-title":"EClinicalMedicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12841-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12841-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:35:05Z","timestamp":1773660905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12841-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12841"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12841-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Medical Ethics Committee of Fudan University (reference number FE21200) in accordance with the tenets of the Declaration of Helsinki and the International Ethical Guidelines for Health-related Research Involving Humans. All participants provided written informed consents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"560"}}